EICHORPublic-registry site landscape for NCT07751341, “A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma”, a Advanced Esophageal Squamous Cell Carcinoma study sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07751341 (registry record) |
| Study title | A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma |
| Official title | A Randomized, Controlled, Open-label, Multicenter Phase II Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma |
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Condition(s) | Advanced Esophageal Squamous Cell Carcinoma |
| Phase | PHASE2 |
| Listed sites | 2 |
| Intervention(s) | SHR-9839(sc) for Injection, SHR-9839(sc) for Injection、Adebrelimab Injection、Paclitaxel for Injection、Cisplatin Injecion |
| Site countries | China |
At Beijing Cancer Hospital — one of the facilities listed on this trial — 17 other studies are actively recruiting Advanced Esophageal Squamous Cell Carcinoma patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07751341.
Eichor generates a preliminary site-risk snapshot for NCT07751341 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
